BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 04/19/23

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in an equity research report published by Aegis Capital Corp. In the rep...

BiondVax participated in the life science industry’s 17th annual Bio-Europe Spring Conference, held this year in Switzerland BiondVax was highlighted as one of the “best ideas” in a NASDAQ-published article after the completion of the conference The company’s biobe...

2023-04-18 02:34:59 ET Biondvax Pharmaceuticals press release ( NASDAQ: BVXV ): FY GAAP EPS of -$0.01 beats by $3.42 . As of December 31, 2022, BiondVax had cash and cash equivalents of $14 million as compared to $17.3 million as of December 31, 2021. For fu...

JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimm...

Earlier this week, President Joseph Biden signed a bill that would end the COVID-19 national emergency with immediate effect. The national emergency was first enacted in 2020, during former President Donald Trump’s administration. Initially, the White House had announced plans to exten...

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “In many compelling ways, BiondVax punches well above its weight compared to...

A study by Stanford Medicine researchers has revealed that individuals with eczema or asthma have a higher chance of developing osteoarthritis . The findings suggest the presence of an allergic pathway that could be treated with existing drugs. Scientists have traditionally thought that wear a...

BiondVax (NASDAQ: BVXV) , which focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has shown, through an ongoing in vivo preclinical proof-of-concept study, that its lead NanoAb candidat...

Climate change presents a significant risk to natural ecosystems and human societies worldwide. Several regions across the world are already experiencing weather disruptions such as flooding , droughts and extreme cold that are impacting human lives and established ecosystems in a myriad o...

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is seeing convincingly positive outcomes for preventing and arrest...